A retrospective cohort study of Thai octogenarians with nonvalvular atrial fibrillation (NVAF) initiating apixaban, dabigatran, rivaroxaban or warfarin was conducted in medical school hospital in Thailand. Patients were recruited from January 1, 2013, to December 31, 2018. The efficacy outcome was early recurrence of stroke or transient ischemic attack (TIA) in 90 days after initiation of oral anticoagulants (OACs). The safety outcome were major bleeding and clinically relevant non-major bleeding complications in 180 days. Continuous variables were compared using independent t test and MannWhitney U test, and categorical variables were compared using chi-square test or Fisher's exact test. Furthermore, hazard ratios and P values were calculated by the use of multivariable Cox's regression analysis.
This is a retrospective cohort study of Thai octogenarians with NVAF. Patients who were prescribed with apixaban, dabigatran, edoxaban, rivaroxaban or warfarin from January 1, 2013, to December 31, 2018 were recruited. The primary efficacy was recurrent ischemic stroke or TIA in 90 days after initiating OACs. The secondary efficacy were recurrent ischemic stroke or TIA in 180 days after initiating OACs. While any bleeding complications were defied as primary safety outcomes. Continuous variables were compared using independent t test and MannWhitney U test, and categorical variables were compared using chi-square test or Fisher's exact test.
Study Type
OBSERVATIONAL
Enrollment
327
Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
Siriraj Hospital, Phramongkutklao Hospital
Bangkok, Thailand
Rate recurrence of stroke or TIA in 90 days
Rate recurrence of stroke or TIA in 90 days after initiation of OACs
Time frame: 90 days after initiation of OACs
Rate recurrence of stroke or TIA in 180 days
Rate recurrence of stroke or TIA in 180 days after initiation of OACs
Time frame: 180 days after initiation of OACs
Rate of major bleeding
Rate of major bleeding in 90 days and 180 days after initiation of OACs
Time frame: 180 days after initiation of OACs
Rate of clinically relevant non-major bleeding
Rate of clinically relevant non-major bleeding in 90 days and 180 days after initiation of OACs
Time frame: 180 days after initiation of OACs
Patients's baseline characteristics associated with recurrence of stroke or TIA as assessed by multivariate cohort analysis
Patients's baseline characteristics associated with recurrence of stroke or TIA in 180 days after initiation of OACs as assessed by multivariate cohort analysis
Time frame: 180 days after initiation of OACs
Patients's baseline characteristics associated with major bleeding and clinically relevant non-major bleeding as assessed by multivariate cohort analysis
Patients's baseline characteristics associated with major bleeding and clinically relevant non-major bleeding in 180 days as assessed by multivariate cohort analysis
Time frame: 180 days after initiation of OACs
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.